Abstract
Background There is still no specific treatment strategies for COVID-19 other than supportive management.
Design A prospective case-control study determined by admittance to the hospital based on bed availability.
Participants Eighteen patients with COVID-19 infection (laboratory confirmed) severe pneumonia admitted to hospital between 20th March and 19th April 2020. Patients admitted to the hospital during the study period were assigned to different beds based on bed availability. Depending on the bed the patient was admitted, the treatment was ozone autohemotherapy or standard treatment. Patients in the case group received ozonated blood twice daily starting on the day of admission for a median of four days. Each treatment involved administration of 200 mL autologous whole blood enriched with 200 mL of oxygen-ozone mixture with a 40 μg/mL ozone concentration.
Main Outcomes The primary outcome was time from hospital admission to clinical improvement.
Results Nine patients (50%) received ozonated autohemotherapy beginning on the day of admission. Ozonated autohemotherapy was associated with shorter time to clinical improvement (median [IQR]), 7 days [6-10] vs 28 days [8-31], p=0.04) and better outcomes at 14-days (88.8% vs 33.3%, p=0.01). In risk-adjusted analyses, ozonated autohemotherapy was associated with a shorter mean time to clinical improvement (−11.3 days, p=0.04, 95% CI -22.25 to -0.42).
Conclusion Ozonated autohemotherapy was associated with a significantly shorter time to clinical improvement in this prospective case-control study. Given the small sample size and study design, these results require evaluation in larger randomized controlled trials.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04444531
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted in compliance with the Declaration of Helsinki and approved by a multidisciplinary human research ethics committee at the institution.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The institution at which the work was performed: Policlinica Ibiza Hospital, Ibiza, Spain
Author contribution statement All authors discussed the results and contributed to the final manuscript.
Dr A Hernández: conceptualization, writing- reviewing and editing.
Dr M Viñals: investigation, validation, data curation.
Dr A Pablos: investigation, validation, data curation.
Dr F Vilás: investigation, validation, data curation.
Dr P J Papadakos: writing-reviewing and editing, supervision, data curation.
Dr D Wijeysundera: writing-reviewing and editing.
Dr S D Bergese: writing-reviewing and editing.
Dr M Vives: Writing- Original draft preparation, formal analysis.
Conflict of interest statement. All the authors declare that there is no conflict of interest.
There is not any financial support for this study.
Clinical trial registration number: NCT04444531
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.
